Citius Pharmaceuticals Inc (NASDAQ:CTXR) insider Leonard L. Mazur acquired 11,000 shares of the stock in a transaction on Thursday, August 24th. The shares were acquired at an average cost of $2.68 per share, for a total transaction of $29,480.00. Following the completion of the transaction, the insider now directly owns 3,337,730 shares in the company, valued at approximately $8,945,116.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Citius Pharmaceuticals Inc (NASDAQ CTXR) opened at 2.77 on Tuesday. The stock’s market capitalization is $22.86 million. Citius Pharmaceuticals Inc has a 12 month low of $2.55 and a 12 month high of $14.85. The firm’s 50-day moving average is $4.39 and its 200 day moving average is $5.68.

ILLEGAL ACTIVITY WARNING: This news story was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/29/citius-pharmaceuticals-inc-ctxr-insider-leonard-l-mazur-acquires-11000-shares.html.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream.

Receive News & Stock Ratings for Citius Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.